血塞通对冠心病不稳定型心绞痛血瘀证患者microRNA的干预作用

发布时间：2018-04-27 05:33

本文选题：冠心病 + 不稳定型心绞痛　；参考：《中国实验方剂学杂志》2017年19期

【摘要】：目的:观察血塞通(XST)治疗及干预冠心病不稳定型心绞痛血瘀证临床疗效及患者外周血hsa-miR-199a-5p,hsa-miR-146b-5p,KIR3DS1,HLA-DPB1,TP53SESN2,NCR1,PRF1表达的影响,阐述XST治疗冠心病血瘀证可能的分子机制。方法:选取心绞痛分级Ⅰ~Ⅲ级的冠心病不稳定型心绞痛血瘀证患者80例,随机分为对照组和治疗组,各40例。对照组给予常规西药治疗+安慰剂,治疗组在常规西药治疗基础上加用血塞通软胶囊,治疗4周。观察治疗前后患者缺血总负荷、西雅图心绞痛质量评分,血流动力学和血脂指标变化,评估XST治疗冠心病血瘀证的临床疗效。实时荧光定量聚合酶链反应(Realtime polymerase chain reaction,Real-time PCR)检测外周血hsa-miR-199a-5p,hsa-miR-146b-5p,KIR3DS1,HLA-DPB1,TP53,SESN2,NCR1,PRF1等基因表达变化。结果:治疗后与对照组比较,治疗组缺血总负荷降低(P0.05);治疗后与对照组比较,治疗组全血黏度、血浆黏度和红细胞刚性指数下降(P0.05);治疗后与对照组比较,治疗组甘油三酯(TG),总胆固醇(TC),低密度脂蛋白-胆固醇(LDL-C)降低(P0.05);治疗后与对照组比较,治疗组KIR3DS1,TP53,SESN2,PRF1上调,hsa-miR-199a-5p,hsa-miR-146b-5p下调(P0.05)结论:XST可有效改善冠心病不稳定型心绞痛血瘀证患者症状,其机制可能与调控hsa-miR-199a-5p,hsa-miR-146b-5p相关。
[Abstract]:Objective: to observe the effect of Xuesaitong XST on the treatment and intervention of blood stasis syndrome of unstable angina pectoris and the expression of hsa-miR-199a-5psa-miR-146b-5pKIR3DS1 HLA-DPB1 TP53SESN2NCR1PRF1 in peripheral blood of patients with coronary heart disease and to elucidate the possible molecular mechanism of XST in the treatment of blood stasis syndrome of coronary heart disease. Methods: 80 patients with unstable angina pectoris and blood stasis syndrome were randomly divided into control group and treatment group. The control group was treated with routine western medicine and placebo, while the treatment group was treated with Xuesaitong soft capsule on the basis of routine western medicine for 4 weeks. The changes of total ischemic load, quality score of Seattle angina pectoris, hemodynamics and blood lipid were observed before and after treatment, and the clinical efficacy of XST in treating coronary heart disease with blood stasis syndrome was evaluated. Real-time polymerase chain real-time PCR was used to detect the expression of hsa-miR-199a-5 psa-miR-146b-5pKIR3DS1 HLA-DPB1 TP53P5NSN2NCR1 / PRF1 in peripheral blood. Results: compared with the control group, the total ischemic load in the treatment group decreased P0.05A, compared with the control group, the whole blood viscosity, plasma viscosity and erythrocyte rigidity index decreased in the treatment group (P 0.05), and compared with the control group after the treatment, the whole blood viscosity, plasma viscosity and erythrocyte rigidity index decreased in the treatment group. Compared with the control group, the triglyceride (TGG), total cholesterol (TC), low density lipoprotein cholesterol (LDL-C) were decreased in the treatment group (P 0.05), and compared with the control group, the treatment group (KIR3DS1TP53SESN2 / PRF1) up-regulated hsa-miR-199a-5phsa-miR-146b-5p (P0.05) conclusion the treatment group can effectively improve the symptoms of coronary heart disease patients with unstable angina pectoris with blood stasis syndrome. The mechanism may be related to the regulation of hsa-miR-199a-5pnhsa-miR-146b-5p.
【作者单位】：中国中医科学院广安门医院;首都医科大学附属北京中医医院;北京中医药大学;
【基金】：国家自然科学基金项目(81473561,81673847)
【分类号】：R259

【相似文献】